SCHEMBL3470077

SCHEMBL3470077

[CH2]c1cccc(OCCOC2CCCCO2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
DHFR P00374 1/20 0.39
CHEK1 O14757 1/20 0.36
TP53 P04637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 1/20 0.35
SIGMAR1 Q99720 3/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
HRH3 Q9Y5N1 4/20 0.33
KCNH2 Q12809 1/20 0.33
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4432583 0.96 KDM4C (0.47) KDM4CMEN1KMT2ANPC1RAB9A
SCHEMBL29639157 0.84 KDM4C (0.50) KDM4CMEN1KMT2ANPC1RAB9A
SCHEMBL12409080 0.84 KDM4C (0.50) KDM4CMEN1KMT2ANPC1RAB9A
SCHEMBL28667185 0.84 KDM4C (0.50) KDM4CMEN1KMT2ANPC1RAB9A
SCHEMBL3806558 0.83 MEN1 (0.61) KDM4CMEN1KMT2ANPC1RAB9A
SCHEMBL3744988 0.82 MEN1 (0.49) KDM4CMEN1KMT2ANPC1RAB9A
SCHEMBL14845812 0.82 KDM4E (0.49) KDM4CMEN1KMT2ANPC1RAB9A
SCHEMBL12193490 0.81 KMT2A (0.67) KDM4CMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL4130417 0.81 MEN1 (0.48) KDM4CMEN1KMT2ANPC1RAB9A
SCHEMBL5546439 0.80 DHFR (0.48) KDM4CMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476286-B2 for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2191832-A1 QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2010-06-02 EP disclosed
US-20040180912-A1 Quinazoline derivatives NOVARTIS AG (CH) 2004-09-16 US disclosed
EP-1401451-A2 QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2004-03-31 EP disclosed
WO-2002102782-A2 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE NOVARTIS AG (CH) 2002-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180912-A1 Quinazoline derivatives PTH1R, PTMS, CALCA KDM4C 1085/4885MEN1 45/4885KMT2A 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.